Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04090710 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04090710 · ClinicalTrials.gov record · last posted 2026-06-17

SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

Study acronym: CYTOSHRINK
StatusActive, Not Recruiting
PhasePhase 2
Started2020-01-29
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 17, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
This trial will evaluate the addition of cytoreductive stereotactic body radiation therapy (SBRT) to standard of care combination ipilimumab and nivolumab (I/N) versus I/N alone for the treatment of metastatic kidney cancer.

Amendment record 16 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 16 times since 2019-09-12; most recent amendment 2026-06-15. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-04-01
Status change Recruiting→Active, Not Recruitingv12
2020-01-29
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT04090710
Lead Sponsor Ontario Clinical Oncology Group (OCOG)
Collaborators: Bristol-Myers Squibb, Hamilton Health Sciences Corporation
Conditions Metastatic Renal Cell Carcinoma
Enrollment 66 participants
Start Date 2020-01-29
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-17